CHINOOK THERAPEUTICS, INC.
CHINOOK THERAPEUTICS, INC. (KDNY): 3 pipeline candidates · ~14 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.3 months
D/E 0.37 · 7% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for CHINOOK THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$129.2M
Quarterly Burn
$61.2M
Runway
14.3 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| atrasentan | Phase 3 |
| bion-1301 | Phase 1/Phase 2 |
| chk-336 | Preclinical |
Frequently asked questions
How many drug candidates are in CHINOOK THERAPEUTICS, INC.'s pipeline?
CHINOOK THERAPEUTICS, INC. (KDNY) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CHINOOK THERAPEUTICS, INC.'s lead drug candidate?
CHINOOK THERAPEUTICS, INC.'s most advanced tracked candidate is atrasentan (Phase 3) for IgA nephropathy (IgAN) and proteinuric glomerular diseases.
What is CHINOOK THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CHINOOK THERAPEUTICS, INC. has approximately 14.3 months of cash runway.
Who is the CEO of CHINOOK THERAPEUTICS, INC.?
Eric Dobmeier is the chief executive officer of CHINOOK THERAPEUTICS, INC. (KDNY).
Get the full picture on CHINOOK THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.